Brandon Folkes: Great. Thank you. And maybe just a high-level one. So I appreciate all the color on the Xtampza and BELBUCA volume growth and the initiatives to drive growth in the back half of the year there. But how do you feel about bringing – or how should we think about bringing in additional commercial assets at this stage? Why you still sort of execute on those initiatives and sort of try and get those assets back to volume growth. Obviously, I imagine it’s going to be an adjacent product, but just how do you think about it strategically in terms of focusing on volume growth versus business development and maybe kind of executing those two in parallel? Thank you.
Joe Ciaffoni: Thanks for the question, Brandon. And I think that gets to our two-pronged strategy. Prong one is maximizing the potential of the pain portfolio. When you think from a business development perspective, the types of things we’re looking at will be lower synergy deals than what we’ve previously done, and that’s really highlighting that we will be pivoting to another therapeutic focus, which will set a second beachhead for the organization and have a separate field force and commercial infrastructure. So – and that’s important to the type of question you’re asking because it will have no disruption to the focus and the people who are dedicated to maximizing the potential of our pain portfolio, and it’s something that we believe will be able to absorb, bring over the individuals and be able to be successful with whatever it is we acquired too.
Brandon Folkes: Great. Thank you very much. Congrats.
Joe Ciaffoni: Thank you.
Operator: Our next question comes from Serge Belanger with Needham & Company. Please state your question.
Serge Belanger: Hi, good afternoon. Just wanted to dig in a little bit on the 1Q performance. Just curious if the usual earlier impacts were more pronounced than usual this year. You talked about gross to net on Xtampza. But what about the BELBUCA and Nucynta gross to net? And then maybe just comment on prescription volumes through the first quarter. Thank you.
Joe Ciaffoni: Okay. Thanks, Serge. I’ll have Colleen start off and take the gross to net question.
Colleen Tupper: Great. Thanks for the question, Serge. So I would say, overall, expectations on gross to nets were aligned with where we saw them come in for the first quarter. To give you a bit of additional context on what we saw by a product beyond Xtampza that I already mentioned. BELBUCA gross to net in the first quarter were 47.8%. Nucynta IR was 41% and Nucynta ER was 40.7%, and those are all in line with our expectations from – and built into our guidance.
Joe Ciaffoni: Yes. And Serge, with regards to prescription trends in the first quarter, I don’t think that there was anything out of the ordinary with the following caveat. This is the first time in the history of Xtampza where we didn’t add any new payer wins. And so it was subjected to that first quarter dynamic. And although the team did an outstanding job, and you can see that in the revenue and gross to net performance of renegotiating those 54% of those contracts that represented 54% of all Xtampza ER prescriptions, we did come off formulary and 10% of those plans, which we think also in the first quarter put some pressure on prescriptions. With regards to BELBUCA, I think it’s in line to what you would historically see.
Serge Belanger: Okay. Thank you. Nice quarter.
Joe Ciaffoni: You got it. Thank you. Appreciate it.
Operator: Our next question comes from Greg Fraser with Truist Securities. Please state your question.
Greg Fraser: Good afternoon both. Thanks for taking the questions. I have a question on the topic of BELBUCA generics. And I’m curious if you have insight into the technical issues that Kemma Research had with this ANDA filing and whether those challenges, if you know what they are, could potentially be faced by other generic filers.
